These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
Artificial intelligence (AI) stocks continue dominating headlines on Wall Street. That probably won't change anytime soon. But investors shouldn't be so distracted by the AI revolution that they forget there are attractive investment opportunities elsewhere. Consider the following three healthcare dividend stocks: AbbVie (ABBV -0.16%), Gilead Sciences (GILD -0.30%), and Becton, Dickinson (BDX -0.71%). All three have crushed broader equities this year, and they still have plenty of upside ahead for investors willing to stay the course. Read on to find out more.
Image source: Getty Images.
- AbbVie
AbbVie did not perform well in the first four months of the year, but it has recovered, and its shares are now up 29% to date, while the S&P 500 has gained 10%. There are several reasons behind the drugmaker's strong performance, perhaps none more important than its two biggest growth drivers, Skyrizi and Rinvoq. These two immunology medicines are performing better than management -- and Wall Street -- expected.
Considering they won't lose patent protection anytime soon, and AbbVie will face no other major loss of patent exclusivity through the end of this decade, we can expect consistent revenue and earnings growth over the medium term. Still, Skyrizi and Rinvoq will eventually face patent cliffs, with the former perhaps starting around 2033. The good news is AbbVie is preparing for that.
AbbVie has strengthened its immunology pipeline through an acquisition and is looking to enter the fast-growing weight-loss market. Further, legacy products, especially its Botox franchise, should perform well over the long term. AbbVie's excellent underlying business will help support its dividend program.
The company is a Dividend King, one of the corporations that have increased their payouts for at least 50 consecutive years. It would take something catastrophic for AbbVie to suspend or decrease its dividends. Until then, expect regular dividend increases alongside solid returns from the company.
- Gilead Sciences
Gilead Sciences' shares have gained 37% this year on the back of improving financial results and solid clinical and regulatory progress. The biotech leader still makes most of its money from its HIV franchise, with medicines like Biktarvy doing much of the heavy lifting. And even though Veklury, a coronavirus medicine, is harming top-line growth, the company has performed well.
Gilead Sciences' third-quarter product sales grew 13% year over year -- its fastest growth rate in this category in over a decade -- to $8.29 billion. Total revenue was $8.30 billion, up almost 7% compared to the year-ago period. Product sales excluding Veklury jumped 16% year over year.
So, as Veklury continues to fade into insignificance, Gilead should record stronger top-line growth, especially as it has strengthened its HIV and oncology businesses this year with new approvals and important label expansions. The biotech giant's outlook appears stronger than it has been in a while, and its dividend program remains attractive. Gilead Sciences offers a forward yield of 2%, and it has increased its payouts by 74.5% over the past 10 years.
- Becton, Dickinson
Becton, Dickinson, a medical technology company, is finally bouncing back after several challenging years. Shares are up 43% to date. One reason for the company's strong performance is its excellent financial results. In the fourth quarter of its fiscal year 2026, which ended Sept. 30, Becton, Dickinson's revenue increased by 5.4% year over year to $5.3 billion. Adjusted earnings per share rose 27.3% year over year to $4.15.
That's a strong performance for the healthcare giant. Another factor behind Becton, Dickinson's results is that it is benefiting from the soaring demand for GLP-1 products and should continue to do so over the medium term.
Growing demand for injectable diabetes and weight-loss medicines is driving significant increases in sales of prefillable syringes and self-injection devices for GLP-1 drugs. With the GLP-1 market projected to expand rapidly over the next five to 10 years, this tailwind may be just starting for Becton, Dickinson.
Meanwhile, the company's underlying business outside of that is resilient and highly predictable. Becton, Dickinson generates most of its revenue from recurring consumables. Finally, Becton, Dickinson is an excellent dividend stock. It is also a Dividend King with a streak of 55 consecutive payout increases.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Worried About Nvidia? 3 Artificial Intelligence (AI) Stocks That May Be Safer Buys Right Now

Further Arrests in the Zondacrypto Scandal. Prosecutor Talks About Three Individuals

Bitcoin developer verifies 164 million unspent coins in just 72 seconds

Druckenmiller Turns Bearish on Copper Prices, Zeroes Out Stock Positions, Says Current Market Visibility is Lowest in Memory

Prediction: These Will Be Nvidia’s and AMD’s Stock Prices by the End of 2027 (Hint: Only 1 Is a Buy).

Where Will Nvidia Stock Be in 3 Years?

U.S. 10-Year Treasury Yield Stays Above 5% for Days Close to 2007 Record

Backpack BP Token Surges 44% on CFTC Approval Talk: What We Know

Prediction: This Will Be Broadcom’s Stock Price by the End of 2028

BPI Becomes The Finney Foundation For Open Technology

We Need To Change Our Management: Ricardo Salinas On Mexico's Future, Bukele And Bitcoin

FinCEN Withdraws Crypto Travel Rule Proposal: What Still Applies

Dec. 9 Expected to Impact S&P 500 as Rate Hike Looms

This Magnificent Growth Stock Just Entered the Artificial Intelligence (AI) Cloud Race, and It Looks Dirt Cheap

Former New York Fed President Dudley: The Fed's 'Painless Disinflation' Strategy Is Doomed to Fail

Solana Foundation AI Agents Account for 76% of OpenRouter Token Usage

FTX 'Old Team' Secures US Futures License, 24/7 Trading on the Horizon

Where Will AMD Stock Be in 5 Years?

Stablecoin holders lose 12000 million USD annually in Treasury interest

CoinGecko Acquired: Two People Started with $200, Once Valued at $500 Million

Micron Has Plunged 36% From Its Peak. Here’s the Price at Which I’d Buy.

Controversial AI Explainability Research Draws Attention from Sam Altman

The Next Hyperliquid Will Emerge from These 6 Companies

A Super Empire on a Fragile Foundation: How Jensen Huang Has Controlled NVIDIA for 33 Years

Microsoft Ignite Conference Kicks Off Today! Focus on Copilot Monetization and AI Computing Returns, Can the Enterprise AI Flywheel Deliver?

IOSG: Bitcoin Needs to Reach $250,000 to Compete with AI in Mining

Wall Street Sees 'Gazumping' Phenomenon as Hedge Funds Compete for Top Talent

Aave Labs Reports: A 97-Person Team Supporting What Kind of DeFi Business?

唐华斑竹 Suggests Optimizing WEEX Platform Token Functionality










